Genentech, MedImmune Settle Synagis Patent Spat

Law360, New York (June 12, 2008, 12:00 AM EDT) -- Biotechnology giant Genentech Inc. has dropped its patent dispute over MedImmune Inc.'s blockbuster drug Synagis, but its battle to uphold the validity of the patent at the center of the litigation continues.

Genentech announced Wednesday that the settlement resolves the litigation over Synagis, a respiratory drug for infants, in addition to a related product called motavizumab that MedImmune is planning to introduce.

The companies dismissed their claims in the U.S. District Court for the Central District of California as part of a settlement Genentech first revealed...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.